David Berman, formerly of AstraZeneca Plc, has been promoted to head of research and development at Immunocore Ltd. He joined the company in September 2018 to help advance Immunocore’s lead product IMCgp100 for patients with uveal melanoma. At AstraZeneca he was responsible for the strategy and execution of the company’s late-stage immuno-oncology programme.
Dr Berman completed his medical degree at the University of Texas Southwestern Medical School and his PhD in the laboratory of Nobel Laureate Alfred Gilman.
Immunocore announced the appointment on 15 January 2019.
Copyright 2019 Evernow Publishing Ltd.